Del 0 - Headache

Novel Synthetic Drugs in Migraine

Häftad, Engelska, 2023

1 159 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.

Published in the series Headache, endorsed by the European Headache Federation, this is the first book on the novel synthetic treatment of migraine with ditans (lasmiditan) and gepants (atogepant, ubrogepant, rimegepant, vazegepant).

Produktinformation

Utgivningsdatum2023-04-29
Mått155 x 235 x 7 mm
Vikt217 g
FormatHäftad
SpråkEngelska
SerieHeadache
Antal sidor109
FörlagSpringer Nature Switzerland AG
ISBN9783030953362

Tillhör följande kategorier

Smärta och smärtbehandling inom Medicin
Klinisk medicin och internmedicin inom Medicin
Olycksfalls- och akutmedicin inom Medicin
Neurologi och klinisk neurofysiologi inom Medicin

Paolo Martelletti is Professor of Internal Medicine at the University 'La Sapienza' of Rome, and Director of the Regional Reference Headache Center at the Sant'Andrea University Hospital in Rome, Italy. He is now developing new research avenues for the study of factors for chronicity, comorbidities, and aspects of health economics in primary headaches; elaboration of rehabilitation protocols in patients with secondary headache as a consequence of medication overuse; study of innovative therapies for the acute treatment and prophylaxis of primary headaches. He is Editor of the Springer Headache book series and Editor-in-Chief of the Journal of Headache and Pain and Editor-in-Chief of Springer Nature Comprehensive Clinical Medicine.Lars Edvinsson is Professor of Internal Medicine at the Faculty of Medicine, Lund University Hospital, Sweden. He is a leading expert in the field of cerebral circulation and migraine and is world recognized for his work on vascular innervation and receptor regulation. His extensive research has been a major contributor to what is known about the roles of the cerebral vasculature in health and diseases such as stroke and primary headaches. Recently, his ground-breaking work on the sensory system has resulted in new medicine being introduced small molecular CGRP-blockers for acute attacks and antibodies towards CGRP or CGRP-receptors as prophylaxis chronic migraine.